ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2873

B-Cell activating Factor Genetic Variants in Systemic Lupus Erythematosus and Lupus Related Atherosclerosis

Evangelos Theodorou1, Adrianos Nezos2, Pinelopi Kostantopoulou3, Maria Tektonidou4, Michael Koutsilieris5 and Clio P. Mavragani5, 1Rheumatology, 251 Hellenic (Greek) Air Force Hospital, Athens, Greece, 2Physiology, Department of Physiology, School of Medicine, National Kapodistrian University of Athens, Athens, Greece, 3Rheumatology Department, General Hospital of Athens "G.Gennimatas", Αthens, Greece, 4Laikon Hospital, Athens University Medical School, Athens, Greece, 5Department of Physiology, School of Medicine, National Kapodistrian University of Athens, Athens, Greece

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: BAFF, Genetic Biomarkers, Lupus, SLE and atherosclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease with an increased atherosclerotic risk compared to healthy population, partially explained by traditional cardiovascular risk factors. Recent data suggest B-cell activating factor (BAFF) as an important contributor in the pathogenesis of both SLE and atherosclerosis. The aim of the current study is to explore whether genetic variants of the BAFF gene increase SLE susceptibility as well as lupus related atherosclerotic risk

Methods: Five single nucleotide polymorphisms (SNPs) of the BAFF gene (rs1224141, rs12583006, rs9514828, rs1041569 and the rs9514827) were evaluated in 234 SLE patients and 200 healthy controls (HC) of similar age and sex distribution by PCR-based assays. Allele, genotype and haplotype frequencies in SLE patients and HC were determined by SHEsis and SNPStats software. All patients underwent ultrasound determination of plaque formation in the carotid arteries. Clinical, laboratory and medication data as well as classical risk factors for cardiovascular disease were recorded in all patients. Patients were followed in the Department of Rheumatology, General Hospital of Athens and Rheumatology Unit First Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece between 2013-2016 and fulfilled the American College of Rheumatology (ACR) criteria for the classification of SLE.

Results: The prevalence of the minor A allele and the AA genotype of the rs12583006 BAFF variant was significantly higher in SLE patients compared to HC (OR [95%CI]: 1.51 [1.12-2.04], p=0.007 and OR [95%CI]: 2.62 [1.04-6.61], p=0.03 in recessive model, respectively). Haplotypes TACAT and TTTAT also conferred a heightened risk for lupus susceptibility. Moreover, the AA genotype of the rs12583006 BAFF variant was significantly higher in SLE patients with evidence of atherosclerotic plaque formation compared to those without plaque after adjustment for age and sex (OR[95%CI]: 5.4 [1.5-19.7], p=0.007 in the recessive model). No other significant associations were detected

Conclusion: BAFF genetic variants increase susceptibility to lupus and lupus related atherosclerosis. These data imply B-cell related factors as potential contributors in the pronounced cardiovascular risk among lupus patients.


Disclosure: E. Theodorou, None; A. Nezos, None; P. Kostantopoulou, None; M. Tektonidou, None; M. Koutsilieris, None; C. P. Mavragani, GSK, 2.

To cite this abstract in AMA style:

Theodorou E, Nezos A, Kostantopoulou P, Tektonidou M, Koutsilieris M, Mavragani CP. B-Cell activating Factor Genetic Variants in Systemic Lupus Erythematosus and Lupus Related Atherosclerosis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/b-cell-activating-factor-genetic-variants-in-systemic-lupus-erythematosus-and-lupus-related-atherosclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/b-cell-activating-factor-genetic-variants-in-systemic-lupus-erythematosus-and-lupus-related-atherosclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology